A trial of nivolumab and TACE or TAE for cancer of the liver (TACE 3)

This trial is looking at adding nivolumab to TACE or TAE for people with cancer of the liver. It is for people who have a type of liver cancer called hepatocellular carcinoma (HCC).

TACE involves injecting a substance (such as a gel or tiny beads) that carry a chemotherapy drug into blood vessels in the liver.

TAE works by reducing the blood supply to the liver.